Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Receivables: 2021-2025

Historic Change in Receivables for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $4.0 million.

  • Oncology Institute's Change in Receivables rose 72061.86% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 5118.07%. This contributed to the annual value of $6.0 million for FY2024, which is 3091.59% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Change in Receivables is $4.0 million, which was up 72061.86% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Change in Receivables ranged from a high of $16.4 million in Q1 2024 and a low of -$6.2 million during Q4 2024
  • Over the past 5 years, Oncology Institute's median Change in Receivables value was $2.1 million (recorded in 2023), while the average stood at $2.4 million.
  • Per our database at Business Quant, Oncology Institute's Change in Receivables soared by 74727.27% in 2022 and then plummeted by 119034.48% in 2024.
  • Over the past 5 years, Oncology Institute's Change in Receivables (Quarter) stood at -$2.0 million in 2021, then surged by 353.5% to $5.1 million in 2022, then crashed by 180.73% to -$4.1 million in 2023, then tumbled by 50.67% to -$6.2 million in 2024, then soared by 164.54% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $8.0 million for Q2 2025, and $985000.0 during Q1 2025.